CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models
The Israeli startup provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio.
Israeli startup CytoReason, which develops computational disease models for predictive insights, has raised $80 million from investors OurCrowd, NVIDIA, Pfizer, and Thermo Fisher. Additionally, the company received credit from Bank Hapoalim that served as a bridge until the new funding was secured. So far, the company has raised a total of $130 million.
Full list of Israeli high-tech funding rounds in 2024
CytoReason has a strategic collaboration with Pfizer that has already brought in over $100 million in revenue. The pharmaceutical giant has also invested in the company in the past. This marks NVIDIA's first investment in CytoReason.
CytoReason will use this investment to expand the application of its models to additional diseases, grow its proprietary molecular and clinical database, and open a representative office in Cambridge, Massachusetts, later this year. The company currently employs 130 people, of which 120 are based in Israel.
Reduced R&D timelines and improved probability of technical and regulatory success (PTRS) are top priorities across life sciences companies. Speed, safety, and accuracy are critical when making asset-related R&D decisions. CytoReason provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio.
Related articles:
Since the company announced the expansion of its Pfizer partnership in 2022, CytoReason has added three major pharma partnerships, expanded its coverage of disease models to central nervous system (CNS)-related diseases, and partnered with leading data organizations.
According to David Harel, co-founder and CEO of CytoReason, "The world understands that data alone is not enough, and that the future of data-driven insights is in data modeling. CytoReason is at the forefront of this revolution in pharma R&D.”
CytoReason is excited to use this new funding to accelerate its growth and further cement its position in the market. This will enable more pharma and biotech companies to increase the speed and accuracy of asset development across therapeutic areas to benefit more patients worldwide.
